by Alex Kadhim
New research identifies a B cell–CD2 costimulatory pathway that enhances adoptive T-cell therapy, improving TIL and CAR-T cell function, metabolism, and tumor control in solid tumors. These...
by Alex Kadhim
Real-world Mayo Clinic data demonstrate the feasibility and effectiveness of tumor-infiltrating lymphocyte (TIL) therapy for metastatic melanoma, highlighting clinical outcomes, immune recovery,...
by ASTCT Talks
In this episode of ASTCT Talks, host Daniel Olson, MD, of the University of Chicago, is joined by Stephanie Goff, MD, of the National Cancer Institute (NCI), and Allison Betof, MD, PhD, of...
by Alex Kadhim
Reporting in Cancer Immunology Research, researchers have demonstrated that potent cytotoxic tumor-infiltrating lymphocytes (TILs) can be generated from immune-excluded chondrosarcomas using...
by Alex Kadhim
Researchers at Northwestern University, with collaborators from the University of Chicago and McGaw Medical Center, have reported the first known case of tumor-infiltrating lymphocyte (TIL)...
by Alex Kadhim
This real-world study demonstrates that lifileucel TIL therapy can deliver strong responses in advanced melanoma, with high response rates and encouraging survival among treated patients. However,...